Experimental drug targets recurrent brain cancer in small early trial
Disease control
Terminated
This early-stage study tested a new drug called RMC-5552 in 7 adults whose glioblastoma (a type of brain cancer) had returned after standard treatment. The drug works by blocking a protein that helps cancer cells grow. The main goals were to find the safest dose and see if the dr…
Phase: PHASE1 • Sponsor: Nicholas Butowski • Aim: Disease control
Last updated May 17, 2026 07:59 UTC